During a recent visit to a hospital conducting clinical trials, Jake Van Naarden, head of Eli Lilly’s oncology unit, uncovered a striking example of inefficiency: a supply closet filled with more than a dozen unused EKG machines. This scenario underscores a broader issue within the pharmaceutical industry, where escalating clinical trial costs continue to pose significant challenges. The presence of such surplus equipment not only indicates potential mismanagement of resources but also reflects the complexities involved in trial logistics and planning.
The implications of this situation are far-reaching. As pharmaceutical companies strive to streamline operations and enhance the efficiency of clinical trials, the existence of excess equipment highlights the need for improved inventory management and strategic resource allocation. Addressing these inefficiencies is crucial for reducing overall trial costs, ultimately impacting the speed and feasibility of bringing new therapies to market.
Start your 7-day trial and see what the database can do →
